Biogen (BIIB) Change in Receivables (2009 - 2026)

Biogen (BIIB) has reported Change in Receivables for 18 consecutive years, with -$103.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Receivables fell 46.88% year-over-year to -$103.4 million; the TTM figure through Mar 2026 stood at -$135.7 million (up 46.15% YoY), while the FY2025 annual figure was -$102.7 million, up 53.8% from the prior year.
• Change in Receivables came in at -$103.4 million for Q1 2026 at Biogen, up from -$114.5 million in the prior quarter.
• The five-year high for Change in Receivables was $240.9 million in Q2 2025, with the low at -$238.2 million in Q4 2024.
• Average Change in Receivables over 5 years is -$16.8 million, with a median of -$40.7 million recorded in 2024.
• The largest YoY upside for Change in Receivables was 748.24% in 2025 against a maximum downside of 662.77% in 2025.
• Year by year, Change in Receivables stood at $200.4 million in 2022, then slumped by 168.76% to -$137.8 million in 2023, then sank by 72.86% to -$238.2 million in 2024, then surged by 51.93% to -$114.5 million in 2025, then increased by 9.69% to -$103.4 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered -$103.4 million, -$114.5 million, and -$158.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.